Upcoming AAD Pediatric Guidelines and Tips for Kids in Dermatology, With Peter Lio, MD

’s editorial team spoke on-site with Peter Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, following his session presented at the 

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

Lio, whose presentation focused on the development of pediatric-specific guidance and the considerations that distinguish care of younger patients from the treatment of adults with atopic dermatitis, highlighted the unique challenges of managing atopic dermatitis in children.

“We are lucky that we have had some really great guideline updates in the last couple of years, and then some even further updates in the adult guidelines just in the last year, because things are moving so quickly,” Lio said. “But there's a gap, because they often do not really focus on pediatrics, and that's important because the rules do not always apply equally.”

 interview, Lio noted that the rapid evolution of the atopic dermatitis treatment landscape has led to several important guideline updates. He emphasized the lack of current recommendations centered on non-adult populations, noting the need for tailored guidance specifically for pediatric patients. A major theme of Lio’s discussion was the long-term perspective required when treating children with atopic dermatitis. Unlike adult patients, families of young children often have questions about how long treatment may be needed and what long-term implications systemic therapies could carry.

Additionally, concerns related to development, growth, school performance, and potential adverse effects commonly represent a notable concern in treatment discussions. Due to this fact, he believes clinicians in dermatology must be prepared to address not only the immediate benefits and risks of medications and management strategies but also broader questions about the future course of therapy.

Lio also highlighted the importance of shared decision-making in pediatric dermatology, noting caring for children with atopic dermatitis can often be a balancing act involving everyone, including patients and their caregivers. Even very young children may have strong views related to treatment preferences, particularly when it comes to injections, topicals, or general drug tolerability. Parents can also diverge on their views regarding the same topics.

Lio highlighted his own view suggesting the successful management of one’s disease often depends on the use of a collaborative approach designed to keepsthe child’s well-being at the center of decision-making. Open communication and help to families navigating questions surrounding safety, efficacy, and long-term care, was described as key for clinicians. They can build trust and improve treatment adherence.

Disclosures: Relevant disclosures for Lio include AbbVie, Almirall, Arbonne, ASLAN Pharmaceuticals, Dermavant, Eli Lilly and Company, Galderma, Johnson & Johnson, L’Oreal, LEO Pharma, Pfizer, Regeneron/Sanofi Genzyme and others.

Lio P, Eichenfield L. Session 8: Anticipated Updates in Pediatric AD Guidelines (AAD 2026 Release). Session presented at: 2026 Revolutionizing Atopic Dermatitis Conference; June 17-19, 2026; Nashville, TN.

Videos

Peter Lio, MD, spoke at the RAD 2026 conference about the upcoming AAD pediatric guidelines for atopic dermatitis.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Michal Meron, MD, is an endocrinology fellow at the Albert Einstein College of Medicine.

Triglyceride-Glucose Index Associated With Risk of End-Stage Liver Disease in MASLD

The triglyceride-glucose (TYG) index, a traditional marker of insulin resistance, has demonstrated its efficacy in predicting incident end-stage liver disease in patients with 

metabolic dysfunction-associated steatotic liver disease (MASLD)

Endocrine Society (ENDO) Annual Meeting 2026

 in Chicago, Illinois, by Michal Meron, MD, an endocrine fellow at the Albert Einstein College of Medicine, these data reflect a recent push for alternative methods of identifying patients at risk of progression, given that existing markers, such as diabetes and 

“The problem of steatohepatitis, or MASLD, as we call it today, is very prevalent and underdiagnosed,” Meron told 

 in an exclusive interview. “We’ve been recommending only screening those who are in high-risk populations, mainly those with diabetes, obesity, and those with known MASLD, but the reality is that many, many people have MASLD – they’re just not being diagnosed, and they are still at risk of progressing to end-stage liver disease.”

The TYG index, first proposed in 2008, is a composite indicator comprised of fasting triglyceride and fasting plasma glucose. The index has particularly high sensitivity and specificity and has been utilized as an alternative biomarker for insulin resistance with limited constraints on cost or time. Additionally, the index has a linear dose-response association with insulin resistance and has shown a significant correlation with a variety of diseases in prior research.

To validate the index’s efficacy in MASLD, Meron and colleagues conducted a nationwide retrospective cohort study based on the medical records data of Clalit Health Services in Israel. Adult patients aged ≥40 years with TYG index measurements taken between 2005 and 2020 were included; patients who had diabetes or chronic liver disease, or who were taking glucose/lipid-lowering medications, were excluded.

The study’s primary outcome was incident end-stage liver disease, which Meron and colleagues noted as including cirrhosis, cirrhosis-related complications, or hepatocellular carcinoma. The team also analyzed associations between sex-stratified TYG quartiles and incident end-stage liver disease by Cox model, adjusting for sex, ethnicity, age, and body mass index (BMI).

A total of 948,317 patients were enrolled and followed for a median of 13.1 years (10,736,020 person-years). Among these patients, 2165 had developed end-stage liver disease during this period (incidence rate: 20.2 per 100,000 person-years; mean age at diagnosis, 56.2 +/- 12.6 years). The highest TYG quartile displayed a 22% increased risk of end-stage liver disease compared to the lowest quartile (adjusted HR, 1.22; 95% CI, 1.08-1.38); these results were consistent across sensitivity analyses. The team also noted an association with sex (

 = .03), with stronger associations in women (HR, 1.37; 95% CI, 1.13-1.65) than in men (HR, 1.16; 95% CI, 0.98-1.37).

Meron and colleagues stated that, while the elevated TYG index has displayed some association with end-stage liver disease risk in the present analysis, further studies are needed to determine whether the index can contribute to risk stratification among patients not currently being offered screening for liver steatosis.

“I would be happy to see if someone else did a similar trial in a different population showing the same trend – we have to see that this repeats itself in other populations,” Meron said. “I think the TYG index will allow us to get a more accurate and 360-degree surrounding view of the patient’s overall metabolic comorbidities. This is something that really comes into play in everyday practice, I believe, even in primary healthcare clinics.”

Editors’ Note: Meron reports no relevant disclosures.

Meron M, Hornik-Lurie T, Rotman-Pikielny P, et al. The Triglyceride-Glucose Index in Non-Diabetic Adults and its Association with End Stage Liver Disease: A Nationwide Cohort Study. Abstract presented at the Endocrine Society (ENDO) Annual Meeting 2026, Chicago, IL. June 13-15, 2026.

Sun Y, Ji H, Sun W, An X, Lian F. Triglyceride glucose (TyG) index: A promising biomarker for diagnosis and treatment of different diseases. Eur J Intern Med. 2025;131:3-14. 

Michal Meron, MD, discusses her recent study indicating the potential role of the TYG index in predicting liver disease among patients without diabetes with confirmed MASLD.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Tulisokibart (MK-7240) became the first anti-TL1A monoclonal antibody to demonstrate clinical remission at week 12 in a phase 3 trial of patients with moderately to severely active 

, according to topline results from the ATLAS-UC induction-only Study 2 announced by Merck on June 22, 2026.

In addition to meeting its primary endpoint, tulisokibart achieved key secondary endpoints and demonstrated a safety profile consistent with previous phase 2 studies.

“These positive Phase 3 induction results for tulisokibart are the first for an anti-TL1A biologic. They represent an important step forward for patients with moderately to severely active ulcerative colitis who, despite available treatments, continue to experience symptoms and do not achieve clinical remission,” said Eliav Barr, MD, senior vice president, head of global clinical development and chief medical officer of Merck Research Laboratories, in a statement. “These results reinforce the potential of this novel approach designed to help address immuno-fibrosis, a key driver of chronic immune dysregulation and disease progression in ulcerative colitis.” 

Tulisokibart is an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), a pathway implicated in both inflammation and fibrosis in inflammatory bowel disease (IBD) and other immune-mediated inflammatory conditions. The therapy is designed to bind both soluble and membrane-bound TL1A with high affinity, preventing its interaction with death receptor 3 (DR3) and interrupting downstream inflammatory signaling.

ATLAS-UC is a phase 3, randomized, double-blind, placebo-controlled program evaluating the efficacy and safety of tulisokibart in adults with moderately to severely active UC. The program includes 2 independent studies: Study 1, which evaluates induction and maintenance treatment, and Study 2, an induction-only trial.

According to Merck, results from Study 2 will be presented alongside data from the ongoing induction and maintenance Study 1 at an upcoming scientific congress and shared with regulatory authorities.

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Merck.com. Merck.com. Published June 22, 2026. Accessed June 22, 2026. 

https://www.merck.com/news/mercks-tulisokibart-met-primary-and-key-secondary-endpoints-in-the-phase-3-atlas-uc-induction-only-study-in-patients-with-moderately-to-severely-active-ulcerative-colitis-uc/

The Edge of a New Frontier: Anti-TL1A Monoclonal Antibodies for Ulcerative Colitis - American College of Gastroenterology. American College of Gastroenterology. Published December 11, 2024. Accessed June 22, 2026. 

https://gi.org/journals-publications/ebgi/kochar_dec2024/

Articles

Merck reported topline phase 3 induction data showing tulisokibart (MK-7240) as the first anti‑TL1A monoclonal antibody to achieve clinical remission at week 12 in moderately to severely active ulcerative colitis. The trial also met key secondary endpoints and showed a safety profile consistent with prior phase 2 experience. Tulisokibart targets TL1A to block interaction with DR3, aiming to interrupt inflammatory signaling and address immuno-fibrosis. Full results from the induction-only study will be presented with ongoing induction/maintenance data and shared with regulators.

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis, First for Anti-TL1A

Scott A. Wilke, MD, PhD, an assistant professor of psychiatry and the Penske Family Chair in Neuromodulation at UCLA Health.

Linda Carpenter, MD, is a professor of psychiatry and human behavior at Brown University. 

This video features Linda Carpenter, MD, Professor of Psychiatry and Human Behavior at Brown University, Andrew Leuchter, MD, Professor and Director of the Neuromodulation Division at UCLA TMS Clinical and Research Services, and Scott Wilke, MD, PhD, Assistant Professor of Psychiatry and Penske Family Chair in Neuromodulation at UCLA Health, discussing accelerated TMS protocols, at-home brain stimulation, and new mechanistic data in the treatment of major depressive disorder. Topics include accelerated TMS for treatment-resistant depression, the 5x5 accelerated rTMS protocol, the SWIFT deep TMS protocol, theta burst stimulation, intermittent theta burst stimulation, deep TMS for MDD, ProlivRx FDA approval, at-home neuromodulation for major depressive disorder, the MOOD trial, physician-directed brain stimulation therapy, TMS insurance coverage, TMS reimbursement 2026, Medicare TMS coverage, TMS after antidepressant failure, prefrontal cortex neuromodulation, intratelencephalic neurons, personalized TMS treatment, TMS patient access, accelerated TMS efficacy, TMS vs conventional treatment, TMS clinical practice, treatment-resistant MDD, TMS psychiatry 2026, brain stimulation therapy for depression, noninvasive brain stimulation, repetitive transcranial magnetic stimulation, rTMS for depression, deep transcranial magnetic stimulation, TMS schedule, TMS protocol comparison, TMS outcomes, PHQ-9 TMS, HDRS TMS, TMS remission rates, TMS response rates, TMS delayed response, TMS maintenance, TMS and antidepressants, TMS adjunctive therapy, neuromodulation psychiatry, interventional psychiatry, brain stimulation MDD 2026.

 TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know

Transcranial magnetic stimulation (TMS) has been 

 since 2008, but for many patients with treatment-resistant depression (TRD), the traditional TMS treatment schedule has been the biggest obstacle to accessing it.

 The standard protocol requires 36 sessions, once daily, over 6 to 8 weeks, a commitment that costs patients their mornings, their commutes, and sometimes their jobs. For those living far from a TMS clinic, it has often meant no treatment at all.

In this video, 3 clinician-researchers, Linda Carpenter, MD, of Brown University; Andrew Leuchter, MD, of UCLA TMS Clinical and Research Services; and Scott Wilke, MD, PhD, Penske Family Chair in Neuromodulation at UCLA Health, walk through what is new in TMS for MDD and what it means for practicing psychiatrists treating patients who have not responded to antidepressants.

What New TMS Protocols for Treatment-Resistant Depression Mean for Clinical Practice

The clinical case for accelerated TMS protocols is building. A retrospective analysis published in March 2026 found that a

, 5 sessions per day over 5 consecutive days, produced efficacy comparable to the conventional 6-week TMS course.

 As Leuchter explained in an interview with 

, the compressed timeline has real implications for patient access and adherence, though insurance reimbursement for accelerated TMS approaches remains a significant gap.

—yet access barriers have limited TMS use in TRD for nearly 2 decades.

—a March 2026 retrospective analysis found comparable outcomes between 5x5 accelerated rTMS and the conventional 6-week daily course (

remission rates for ProlivRx vs sham in the MOOD trial (

 — Medicare reimburses up to 2 TMS sessions per day; accelerated protocols of 5 or more sessions per day remain unreimbursed as of 2026.

On the at-home neuromodulation front, the

 FDA approved Neurolief’s ProlivRx in January 2026

, the first prescription, physician-directed at-home brain stimulation therapy for MDD, indicated for adults who did not achieve satisfactory improvement from ≥ 1 prior antidepressant.

 Carpenter, who led the MOOD trial studying the device as adjunctive therapy, describes how the physician-directed model works in practice and what the current reimbursement landscape looks like for patients.

Wilke adds mechanistic context on how accelerated intermittent theta burst stimulation acts on specific cell types in the prefrontal cortex and what that could mean for personalizing TMS treatment for MDD.

For a deeper dive into the data behind each of these developments, read the full written feature here: 

TMS for MDD Reimagined: Faster, Fewer Visits, and Now at Home

Editor’s note: Reported disclosures include Neuronetics and Janssen Pharmaceuticals for Carpenter and Abbott Laboratories for Leuchter. Wilke has no reported disclosures.

Patel, P. The FDA Approved TMS For Treating Depression In 2008. TMS Institute of Arizona. Published May 13, 2025. 

https://tmsinstitute.co/the-fda-approved-tms-for-treating-depression-in-2008/

Leuchter A. Accelerated 5×5 rTMS Matches Standard Protocols in TRD, With Andrew Leuchter, MD. HCPLive. Published on March 24, 2026. Accessed June 18, 2026. 

https://www.hcplive.com/view/accelerated-5-5-rtms-matches-standard-protocols-trd-andrew-leuchter-md

Derman C. Accelerated Deep TMS Matches Standard Outcomes in TRD in 6 Days. HCPLive. Published on March 18, 2026. Accessed June 18, 2026. 

https://www.hcplive.com/view/accelerated-deep-tms-matches-standard-outcomes-trd-6-days

Derman C. FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD. HCPLive. Published on January 13, 2026. Accessed June 18, 2026. 

https://www.hcplive.com/view/fda-approves-proliv-rx-first-home-neuromodulation-mdd

Derman C. TMS for MDD Reimagined: Faster, Fewer Visits, and Now at Home. HCPLive. Published on May 15, 2026. Accessed June 18, 2026. 

https://www.hcplive.com/view/tms-mdd-faster-fewer-visits-home

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know

Experts review standard diagnostic criteria for diabetes, then detail phenotypic and clinical features that support—but do not definitively confirm—a diagnosis of type 2 diabetes, emphasizing the limitations of BMI-based assumptions.

Beyond BMI: Clinical Features Supporting a True Type 2 Diabetes Diagnosis

In this portion of the discussion, Samson asks Umpierrez to walk through how the 2026 AACE classification algorithm helps confirm or question a diagnosis of type 2 diabetes in clinical practice. Umpierrez begins by reviewing that the biochemical thresholds used to diagnose diabetes—fasting plasma glucose of at least 126 mg/dL, 2-hour glucose of at least 200 mg/dL on oral glucose tolerance testing, hemoglobin A1c of at least 6.5%, or a random glucose of at least 200 mg/dL in the setting of hyperglycemic symptoms—apply to both type 1 and type 2 diabetes. These criteria, he notes, do not distinguish between etiologies but define the presence of diabetes itself.

To support a diagnosis of type 2 diabetes, Umpierrez outlines several clinical features that are commonly associated with this phenotype. These include overweight (body mass index [BMI] 25–29.9 kg/m²), obesity (BMI ≥30 kg/m²), a history of weight gain, prior gestational diabetes, a strong family history of type 2 diabetes, and physical examination findings of insulin resistance, such as acanthosis nigricans. He emphasizes acanthosis as one of the most important physical signs indicating significant insulin resistance. Samson and Umpierrez agree that these features can increase the likelihood of type 2 diabetes but must be interpreted within a broader clinical context.

However, both experts stress the limitations of relying on BMI alone. Umpierrez notes that BMI cutoffs are based on Western populations and may differ by race and ethnicity—for example, lower BMI thresholds in some Asian groups may better reflect cardiometabolic risk. He cites data from the adult-onset type 1 diabetes cohort discussed earlier, in which approximately 59% of patients with late-onset type 1 diabetes were overweight, and about 12% of adults with type 2 diabetes had a normal BMI. Samson and Umpierrez use these data to reinforce a key message of the 2026 AACE algorithm: although BMI and obesity are important clues, neither should be treated as definitive evidence of type 2 diabetes in adults with hyperglycemia.

Video Series

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.
intro:

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 06/14

Butler explains why the urine albumin-to-creatinine ratio belongs in routine heart failure risk assessment and where the open questions remain.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Chronic Kidney Disease

The Value of Albuminuria in Heart Failure Risk Assessment, with Javed Butler, MD, MBA

Javed Butler, MD, MBA, discusses how aldosterone synthase inhibition could shift treatment across heart failure, CKD, and resistant hypertension.

The Role of Aldosterone & Aldosterone Synthase Inhibitors in Cardiology, with Javed Butler, MD, MBA

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

MOMENTUM data suggest hypercortisolism prevalence reached 43.6% among individuals with resistant hypertension and an eGFR below 45 mL/min/1.73 m².

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

MOMENTUM: Lower Kidney Function Could Signal Hypercortisolism in Resistant Hypertension

Pediatric studies show dupilumab boosts height gains, eases caregiver-reported symptoms by week 2, and maintains strong skin clearance for 3 years.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dupilumab Improves Growth, Skin, & Caregiver Burden Across Pediatric AD Spectrum

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Podcasts

Phase 3 FIND-CKD data show finerenone slows kidney function decline in non-diabetic chronic kidney disease, extending the agent's role beyond diabetic CKD.

Don’t Miss a Beat

The Don't Miss a Beat Podcast is a regular news roundup of the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases. Don’t Miss a Beat as Steve Greene, MD, and Muthu Vaduganathan, MD, MPH, critically examine recent advances in clinical care and research with perspectives from global experts in the field.

Don't Miss a Beat: Finerenone, FIND-CKD, and the Evolution of CKM, with Katherine Tuttle, MD

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

Atherosclerotic Cardiovascular Disease

Dyslipidemia

Lipoprotein(a) Testing Prevalence Remains Just 1.1% in US Adults

This Q&A interview with Mona Shahriari, MD, highlights key atopic dermatitis tips, new developments, and themes from her session at RAD 2026.

Q&A: What Are the Most Exciting New Atopic Dermatitis Developments? With Mona Shahriari, MD

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Yale Study: Two-Thirds of Online GLP-1 Prescriptions Require No Clinician-Patient Interaction

Mona Shahriari, MD, spoke about the evolving understanding of atopic dermatitis as a systemic disease, the complexities of treatment selection, and more.

Latest News

Upcoming AAD Pediatric Guidelines and Tips for Kids in Dermatology, With Peter Lio, MD

Triglyceride-Glucose Index Associated With Risk of End-Stage Liver Disease in MASLD

Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis, First for Anti-TL1A

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know

Beyond BMI: Clinical Features Supporting a True Type 2 Diabetes Diagnosis